WASHINGTON (Reuters) - An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
Lake forest health and fitness http://ift.tt/1f9rUC6
No comments:
Post a Comment